Straub CE marks endovascular catheters for further indications
This article was originally published in Clinica
Executive Summary
Straub Medical has CE marked its new-generation Rotarex S and Aspirex S families of rotational endovascular catheters for additional indications and subsequently upgraded the classification of the devices from Class II to III. The catheters, in combination with the Straub Medical Drive System, can now be marketed for the percutaneous transluminal removal of material from occlusions of all blood vessels outside the cardiopulmonary, coronary and cerebral circulations. Both catheters may be used in native blood vessels or vessels fitted with stents, stent grafts or native or artificial bypasses. Aspirex S catheters are intended to be used for the removal of fresh thrombotic or thromboembolic material, and Rotarex S catheters are designed to remove thrombotic, thromboembolic and atherothrombotic material from fresh, subacute and chronic occlusions. The Wangs, Switzerland company initially CE marked the devices in 1999.
You may also be interested in...
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.